Jessica Merrill
Senior Editor
Latest From Jessica Merrill
Cartesian Looks To Chart The Way For CAR-T In Autoimmune Disease
A Phase IIb trial testing Cartesian’s autologous mRNA-engineered CAR-T therapy for the treatment of generalized myasthenia gravis (MG) met the primary endpoint.
Eisai Regains Full Control Of ADC Program After Bristol R&D Reprioritization
The Japanese pharma said it plans to accelerate development of the antibody-drug conjugate farletuzumab ecteribulin for solid tumors and will develop it independently.
Abecma Or Bust: 2seventy Sells Final Research Program To Novo
2seventy bio sold full rights to a hemophilia A program and in vivo gene editing technology to partner Novo Nordisk.
Jazz’s Suvecaltamide Fails In Tremor Trial, But Parkinson’s Study Continues
A Phase IIb trial evaluating suvecaltamide failed to show a statistically significant benefit versus placebo on an assessment scale for essential tremor.
Merck’s Newly Approved Capvaxive Could Have Edge Over Prevnar 20 In Adults
The 21-valent pneumococcal vaccine will face an entrenched competitor in Pfizer’s Prevnar 20, but Merck believes Capvaxive has a competitive advantage because it protects against serotypes specific to adults.
Takeda’s Soticlestat Fails In Seizure Trials
Two Phase III studies testing soticlestat, licensed from Ovid, in Dravet and Lennox-Gastaut syndromes failed to meet their primary endpoints on improvement in seizure frequency.